134 related articles for article (PubMed ID: 20332141)
21. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
[TBL] [Abstract][Full Text] [Related]
23. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
24. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
25. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
Cheah CY; Mistry HE; Konoplev S; Fowler NH
Leuk Lymphoma; 2016 Aug; 57(8):1974-6. PubMed ID: 26762971
[No Abstract] [Full Text] [Related]
26. Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma- Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma.
Simon Z; Virga B; Pinczés L; Méhes G; Miltényi Z; Barna S; Szabó R; Illés Á
Pathol Oncol Res; 2021; 27():625529. PubMed ID: 34257590
[TBL] [Abstract][Full Text] [Related]
27. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
[TBL] [Abstract][Full Text] [Related]
28. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
29. [Treatment results of Hodgkin's lymphoma].
Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
[TBL] [Abstract][Full Text] [Related]
30. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
31. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Hagberg H; Gisselbrecht C;
Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
[TBL] [Abstract][Full Text] [Related]
33. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment--the Pediatric Oncology Group experience.
Karayalcin G; Behm FG; Gieser PW; Kung F; Weiner M; Tebbi CK; Ferree C; Marcus R; Constine L; Mendenhall NP; Chauvenet A; Murphy SB
Med Pediatr Oncol; 1997 Dec; 29(6):519-25. PubMed ID: 9324338
[TBL] [Abstract][Full Text] [Related]
34. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.
Glass B; Ziepert M; Reiser M; Freund M; Trümper L; Metzner B; Feller A; Loeffler M; Pfreundschuh M; Schmitz N;
Ann Oncol; 2010 Nov; 21(11):2255-2261. PubMed ID: 20444844
[TBL] [Abstract][Full Text] [Related]
35. Treatment of lymphocyte-predominant Hodgkin lymphoma.
Engert A
Ann Oncol; 2008 Jun; 19 Suppl 4():iv45-6. PubMed ID: 18519402
[No Abstract] [Full Text] [Related]
36. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
[TBL] [Abstract][Full Text] [Related]
37. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents.
Murphy SB; Morgan ER; Katzenstein HM; Kletzel M
J Pediatr Hematol Oncol; 2003 Sep; 25(9):684-7. PubMed ID: 12972802
[TBL] [Abstract][Full Text] [Related]
38. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
[TBL] [Abstract][Full Text] [Related]
39. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
[TBL] [Abstract][Full Text] [Related]
40. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.
Eyre TA; Gatter K; Collins GP; Hall GW; Watson C; Hatton CS
Am J Hematol; 2015 Jun; 90(6):E103-10. PubMed ID: 25715900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
